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Abstract 
We report on the synthesis, characterization, stability and pharmacokinetics of novel iron based 
contrast agents for magnetic resonance imaging (MRI). Statistical copolymers combining multiple 
phosphonic acid groups and poly(ethylene glycol) (PEG) were synthesized and used as coating agents for 
10 nm iron oxide nanocrystals. In vitro, protein corona and stability assays show that phosphonic acid 
PEG copolymers outperform all other coating types examined, including low molecular weight anionic 
ligands and polymers. In vivo, the particle pharmacokinetics is investigated by monitoring the MRI signal 
intensity from mouse liver, spleen and arteries as a function of the time, between one minute and seven 
days after injection. Iron oxide particles coated with multi-phosphonic acid PEG polymers are shown to 
have a blood circulation lifetime of 250 minutes, i.e. 10 to 50 times greater than that of recently 
published PEGylated probes and benchmarks. The clearance from the liver takes in average 2 to 3 days 
and is independent of the core size, coating and particle stability. By comparing identical core particles 
with different coatings, we are able to determine the optimum conditions for stealth MRI probes. 
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1 – Introduction 
Magnetic Resonance Imaging (MRI) is one of the most widespread non-invasive imaging techniques in 
clinical practice and research. Current MRI methods are based on the intrinsic contrast of soft tissues 
and vessels, and provide important information on a broad range of pathologies. Novel imaging 
techniques have emerged over the last decade, in particular techniques based on the use of contrast 
agents.1-3 Most studied MRI contrast agents are gadolinium chelates and magnetic particles. Made from 
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iron oxide, magnetic particles provide several advantages among which a substantial biodegradability 
over time and an absence of cytotoxicity. In addition, depending on their size the particles can be used 
as positive or negative contrast agents, leading to an enhancement of longitudinal and transverse 
proton relaxation rates.4-6 
For applications, the pharmacokinetic profile of the MRI probes has to be known. Absorption, in vivo 
biodistribution, metabolic transformation and elimination from the tissues and organs are the primary 
mechanisms involved in pharmacokinetics. In the blood pool, nanoparticles administered intravenously 
are recognized from plasma proteins, which adsorb at the particle surface spontaneously.7-12 The protein 
binding process, known as the protein corona formation prevents the particles to interact specifically 
with potential targets. Simultaneously, protein adsorption activates the particle uptake by the 
mononuclear phagocytic system through the circulating macrophages and monocytes. The two-step 
opsonization mechanism described here is responsible for the particle elimination from the blood 
stream and for their accumulation in unrelated organs, typically the liver and the spleen.13 As a result, 
commercial contrast agents using iron oxide cores (e.g. Endorem® from Guerbet, Resovist® and Cliavist® 
from Bayer) were first designed for imaging hepatic lesions and tumors.1 Ever since, iron oxide particles 
have been surveyed in the context of other clinical applications, including heart transplantation, brain 
lesions imaging and tumor targeting.2,6,14-16 
To prevent opsonization, studies have shown that neutral hydrosoluble polymers such as poly(ethylene 
glycol) (PEG) or polysaccharides are efficient.13,17-20 Tethered at the chain extremity or from several 
monomeric units, the polymers in aqueous environment form a swollen brush that acts as a protective 
layer against protein adsorption and particle aggregation. In this context, efforts were mainly directed 
towards the molecular weight effect on the in vitro stability and in vivo stealthiness.15,21-27 From in vivo 
pharmacokinetics studies, Leal et al. have found an optimum PEG value of 3 kDa,25 whereas particle 
accumulation in tumor was found to be efficient with 10 kDa polymers.15 Recently, Ruiz et al. reported a 
doubling of the residence time in blood for PEG conjugated iron oxide particles, and a reduction in the 
liver and spleen uptake.21,22 In some of the previous studies, the PEGylated contrast agents tested were 
prepared from 10 nm particles; however it was found that during synthesis or functionalization the 
particles aggregated and formed large clusters containing tens to hundreds of particles.15,21,22,26,28 For 
aggregates, additional parameters such as size and morphology were found to affect the MRI contrast 
properties and the biodistribution in vivo. These properties were also different from those of single 
nanoparticles. 
Another crucial issue in particle functionalization is the nature and strength of the link between the coat 
and the inorganic surface. A wide variety of techniques based on covalent or non-covalent binding are 
now achievable, including ligand adsorption, layer-by-layer deposition or surface-initiated 
polymerization.29 Non-covalent strategies based on the assembly of separately synthesized components 
are known to exhibit enhanced yields in terms of quantity of particles produced.30 Novel 
macromolecular architectures obtained by radical polymerization were also considered.31 Na et al. 
designed multi-dentate catechol and PEG derivatized oligomers that provide colloidal stability over a 
broad range of pH and electrolyte concentrations.32 Single or multiple phosphonic acid based polymers 
were also synthesized.31,33-35 Phosphonate groups are known to have a higher affinity towards metallic 
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atoms or metal oxides compared to sulfonates and carboxylates, and are hence able to build stronger 
links with surfaces. Sandiford et al. exploited PEG polymer conjugates containing a terminal bis-
phosphonic acid group for binding to magnetic nanoparticles.34 
We have recently shown that multi-phosphonic acid PEG-copolymers with up to 4 anchoring groups per 
chain conferred considerable stabilization to 10 nm iron oxide cores. The coated particles were found to 
be stable for months in extreme salt and pH conditions, as well as in cell culture media. In a previous 
work, multi-phosphonic acid PEG coated particles were tested against fibroblast and macrophage 
cultures and exhibited exceptional low cellular uptake.12 Here, these newly coated particles are assessed 
in vivo using a live mouse model. MRI is particularly suited for this study as it provides spatial and 
temporal resolved images with high contrast. The present survey reveals that the phosphonic acid PEG 
copolymers with multiple anchoring groups are able to prolong the particle lifetime in the blood up to 3 
hours, i.e. 50 times greater than that of anionic particles or Cliavist® benchmark, and 10 times greater 
than that of recently published PEGylated probes.21-23 A qualitative model taking into account the 
uptake and clearance is proposed and is found to be appropriate for all contrast agents studied. By 
comparing identical core particles with different coating, we are able to determine the optimum 
conditions for stealth MRI probes.  
 
 
2 - Materials & Methods 
2.1 - Iron oxide nanoparticles and Coating 
2.1.1 - Iron oxide nanoparticles 
Iron oxide nanoparticles were synthesized by alkaline co-precipitation of iron(II) and iron(III) salts.36,37 
The salts were dissolved in a hydrochloric solution and co-precipitated by a concentrated base 
(ammonia, NH3). The particles were then concentrated magnetically and the supernatant was removed. 
The concentrated phase was washed with water using magnetic sedimentation followed again by 
supernatant removal. Nitric acid (HNO3) was then added to the particles down to pH 1.5. Addition of a 
large excess of ferric nitrate at water boiling temperature led to the oxidation of magnetite into stable 
maghemite nanocrystals. The nanoparticles were sorted according to their size by successive phase 
separation steps.38 At pH 1.5, the particles are positively charged and have nitrate counterions adsorbed 
on their surfaces. The resulting interparticle interactions are repulsive and impart an excellent stability to 
the dispersion.37,39 Here, two -Fe2O3 nanoparticles batches (diameter 6.8 nm and 13.2 nm) were 
synthesized (Figs. 1a-d). The magnetic and geometric size distributions were obtained from vibrating 
sample magnetometry (VSM) and from transmission electron microscopy (TEM), respectively. Table I 
provides a list of the diameters and dispersities (ratio between standard deviation and average diameter) 
obtained from these two techniques.  
 
 6.8 nm -Fe2O3 
nanoparticle 
13.2 nm -Fe2O3 
nanoparticle 
diameter VSM (nm) 6.7 10.7 
dispersity VSM 0.21 0.33 
diameter TEM (nm) 6.8 13.2 
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dispersity TEM 0.18 0.23 
molecular weight  
     (Da) 1.3×106 12×106 
hydrodynamic diameter    
(nm) 
14 27 
 
Table I: Characteristics of the iron oxide particles used in this work. The bare particle size and size dispersity were 
determined by vibrating sample magnetometry (VSM) and by transmission electron microscopy (TEM). The weight-
averaged molecular weight  
     was obtained from static light scattering.
40
    is the bare particle hydrodynamic 
diameter in water. 
 
 
The nanoparticle magnetization was also measured using VSM and its value was found slightly lower 
than that of bulk maghemite41,42 (2.9105 A m-1 instead of 3.9105 A m-1). The particle crystallinity was 
studied by electron microdiffraction scattering. Five diffraction rings characteristic of the maghemite 
structure were observed (S1-S4). In the dispersed state, light scattering techniques allowed the 
measurements of the weight-averaged molecular weight and of the hydrodynamic diameter for the 
particles.40 Throughout the paper, the concentrations are expressed in terms of the iron molar 
concentration, noted [Fe]. For instance, the [Fe] = 5 mM dispersion used for the intravenous injection 
corresponds then to a weight concentration of 400 µg mL-1. Assuming a blood pool of 1 mL for wild-type 
BALB/c mice (age 8 weeks), the concentration of circulating particles is estimated at 40 µg mL-1. The 
contrast agent used as a benchmark, Cliavist® was commercialized by the company Bayer (Germany). 
According to supplier specifications, the Cliavist® dispersion has an iron concentration of 500 mM and 
contains 4 nm magnetic core particles aggregated into 55 to 65 nm clusters.1 The 1400 Da 
carboxydextran molecules used in the formulation serve both as a linker for the maghemite 
nanocrystals, the polymer role being indeed to prevent the dispersion sedimentation.  
 
 
Figure 1: a, b) Transmission electron microscopy (TEM) of the 6.8 and 13.2 nm iron oxide nanoparticles. The bars 
are 20 nm and 50 nm respectively. c, d) Particle size distribution determined by TEM. e) Table showing the chemical 
formula, charge and molecular weight of the organic coatings used in this study. For the phosphonic acid PEG 
copolymer, only the PEG molecular weight is indicated.  
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2.1.2 – Coating 
In this section, we describe the macromolecules and protocols used to coat the iron oxide particles (Fig. 
1e). Poly(ethylene glycol methacrylate-co-dimethyl(methacryoyloxy) methyl phosphonic acid), 
abbreviated in this work phosphonic acid PEG copolymer was synthesized by Specific Polymers®, France 
(http://www.specificpolymers.fr/). The synthesis was carried out by free radical polymerization of PEG-
methacrylate (PEGMA, SP-43-3-002, CAS: 26915-72-0) and dimethyl(methacryoyloxy)methyl 
phosphonate (MAPC1, SP-41-003, CAS: 86242-61-7) monomers. Synthesis details can be found in 
previous reports.12,43 The phosphonic acid PEG copolymers were characterized from 1H NMR and 31P 
NMR using a Bruker Avance 300 spectrometer operating at 300 MHz. For the copolymers, a molar-mass 
dispersity of 1.8 was obtained by size exclusion chromatography on PolyPore column using THF as eluent 
and polystyrene standards. From the molar equivalent of acid groups obtained from NMR and molecular 
weight determination, the number of phosphonic acids and PEG segments was estimated. This number 
was found to be 3.1 ± 0.2 and 3.7 ± 0.2 for copolymers with PEG2K and PEG5K, respectively (Table II). Here 
and below, the error bars are defined as the standard deviations (SD). These determinations confirm the 
existence of multiple functional groups on the same polymer backbone.  
 
polymer name 
acid group 
meq/g 
functional group 
per chain 
PEG 
density 
6.8 nm 
PEG 
density 
13.2 nm 
copolymer  
with PEG 2000 Da 
0.873 3.1 ± 0.2 1.9 1.1 
copolymer  
with PEG 5000 Da 
0.349 7.4± 0.4 2.0 1.1 
 
Table II: Structural parameters of the PEG copolymers used in this work. The first column denotes the molar 
equivalent of acid groups per gram (            ) of polymer as determined by 1H NMR. The numbers of the 
functional groups are determined from the molecular weight and from the molar equivalent of acid groups.
12
 The 
error bars are here defined as the standard deviations (SD). 
 
For the coating, we used a protocol derived in 2008.44,45 Dispersions of oppositely charged iron oxides 
and phosphonic acid PEG copolymers at the same concentration (  = 0.1 wt. %) and same    (    ) 
were mixed at increasing volume ratios   between 10-3 and 103. The    of the mixed solution was then 
raised to 8 by ammonium hydroxide addition, leading to well-dispersed coated particles. The mixed 
polymer/particle dispersion stability diagram was investigated by dynamic light scattering (Fig. S5). By 
plotting the hydrodynamic diameter against the mixing ratio  , a transition between individual coated 
particles and micron-sized aggregates occurs at the critical value,   . The existence of a critical mixing 
ratio suggests that adsorption occurred via a non-stoichiometric electrostatic binding process.44,45 The 
model assumes that for each value of  , the polymers are equally distributed among the particles in the 
dispersion.45 Below   , the iron oxide surfaces are saturated with polymers, the functional end-groups 
exceeding the number of binding sites. Above, the coverage is incomplete and the particles precipitate 
upon    increase (as uncoated particles do). Here, we exploit this feature to derive the number of 
adsorbed chains per particle     :
12 
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where   
     and   
    are the particle and polymer molecular weights, respectively. For PEG2K on 6.8 
nm and 13.2 nm particles,    = 1.3 and 5, leading to a number of adsorbed polymers      = 97 and 207, 
respectively. For PEG5K,    = 0.5 and 2, resulting in      = 43 and 88 (Table S5). These     -values 
correspond to a PEG density of 1 - 2 nm-2. With zeta potentials of -6 mV, electrokinetic measurements 
confirmed that the multi-phosphonic acid PEG coated particles were globally neutral (S4). Before use, 
the dispersions were finally dialyzed against deionized water using a 50 kD cut-off membrane to remove 
the excess polymer, and further concentrated by ultrafiltration. They were then autoclaved (Tuttnauer 
Steam Sterilizer 2340M) at 120 °C and atmospheric pressure during 20 min to prevent bacterial 
contamination, and stored at 4 °C in a secure environment. 
Citric acid is a weak triacid of molecular weight   = 192 Da, with acidity constants pKA1 = 3.1, pKA2 = 4.8 
and pKA3 = 6.4. Surface charge complexation with citric acid was performed during the synthesis through 
simple mixing. At pH 8, citric acid molecules are ionized, and particles are coated with citrate ions. As 
ligands, citrates are characterized by adsorption isotherms and adsorbed species are in equilibrium with 
free citrates in the bulk. The free citrate concentration was kept at the value of 8 mM,39 both in DI-water 
and in culture medium. The hydrodynamic citrate coated particle diameter was identical to that of bare 
particles, indicating a layer thickness under 1 nm.  
Poly(sodium acrylate), the salt form of poly(acrylic acid) with a weight-average molecular weight    = 
2.1 kDa and a dispersity of 1.7 was purchased from Sigma Aldrich and used without purification. To 
adsorb polyelectrolytes on the particles, the precipitation-redispersion protocol was applied.41 The 
precipitation of the iron oxide dispersion by PAA2K was performed in acidic conditions (   ). The 
precipitate was then separated by magnetic sedimentation and its pH was increased by ammonium 
hydroxide addition. The precipitate redispersed spontaneously at pH8. PAA2K coated γ-Fe2O3 
hydrodynamic sizes were around 4 – 6 nm larger than the hydrodynamic diameter of the uncoated 
particles, indicating a corona thickness of 2 – 3 nm. Electrophoretic mobility and zeta-potential values 
are provided in the Supporting Information section (S4). As for the multi-phosphonic acid PEG coated 
particles, the dispersions were dialyzed and autoclaved to prevent bacterial contamination.  
 
 
2.2 - Methods 
2.2.1 - Dynamic light scattering (DLS) 
Light scattering experiments were performed on a NanoZS spectrometer (Malvern) at the wavelength of 
633 nm and in backscattering configuration (scattering angle 173°). From the scattered intensity 
evolution, the second-order autocorrelation function of the light is calculated and analyzed using 
different procedures provided by the instrument software. These procedures are the cumulant method 
and the CONTIN algorithm. Both gave consistent values for the hydrodynamic diameter   . As 
mentioned previously, the nanoparticle hydrodynamic diameters are found to be systematically larger 
than those obtained by other techniques, in particular by electron microscopy and magnetometry (Table 
I). The reason for this difference is related to the particle size distribution, along with the fact that light 
scattering is sensitive to the largest objects of the distribution. 
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2.2.2 - Cell Culture 
Adherent cells from mouse hepatocyte cells BWTG3 were studied. Hepatocyte cells BWTG3 were grown 
in T25-flasks as a monolayer in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose (4.5 g L-
1) and stable glutamine (PAA Laboratories GmbH, Austria). The medium was supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin (PAA Laboratories GmbH, Austria). 
Exponentially growing cultures were maintained in a humidified atmosphere of 5% CO2 and 95% air at 
37°C, and in these conditions the plating efficiency was 70 – 90% and the cell duplication time was 12 – 
14 h. Cell cultures were passaged twice weekly using trypsin–EDTA (PAA Laboratories GmbH, Austria) to 
detach the cells (6 millions in average for T25 flasks) from their culture flasks and wells. The cells were 
pelleted by centrifugation at 1200 rpm for 5 min. Supernatants were removed and cell pellets were re-
suspended in assay medium and counted using a Malassez counting chamber.  
 
2.2.3 - Toxicity assay 
The method measured the cellular mitochondrial activity. Subconfluent cell cultures (60% confluency at 
treatment time) on 96 well plates were treated with 100 µL/well of nanoparticles at different 
concentrations for 24 h, culture medium was removed, cells were rinsed with culture media without 
phenol red and incubated with 100 µL/well of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulphophenyl)-2H-tetrazolium (WST-1, Roche Diagnostics), diluted 1/10 in culture medium without 
phenol red for 1 to 4 h. The assay is based upon the reduction of the tetrazolium salt WST-1 to formazan 
by cellular dehydrogenase. The generation of the dark yellow colored formazan was measured at 450 
nm in a multiwell-plate reader against a blank containing culture media and WST-1 and it was corrected 
from the absorbance at 630 nm. The supernatant optical density is directly correlated to cell number. 
 
2.2.4 – Relaxometry 
Images were acquired with a 7 Tesla spectrometer equipped with a 1H radiofrequency linear coil of inner 
diameter 40 mm (Bruker, Karlsruhe Germany).    and    relaxation times were measured on 200 µL 
solutions with increasing iron concentrations, [Fe] = 0.02, 0.05, 0.1, 0.2 and 0.5 mM to determine the 
longitudinal and transverse relaxivities    and   . For   -measurement, a saturation sequence with 8 
different repetition times from 60 ms to 15 s was used to evaluate the proton spin-lattice recovery. The 
field of view was of a 3 3 0.15 cm3 with a pixel resolution of 0.234 0.234 1.5 mm3 in all protocols. 
For   -measurement, a sequence with 32 sequential echo times from 11 ms to 385 ms was applied to 
follow the decay of the proton spin-spin relaxation. The total scan time was 30 min. The relaxivities rates 
     were obtained by adjusting the signal intensity of each agent at different concentrations using:
46 
           [Fe]      
  . These measurements were made in physiological saline solution and in 
DMEM with serum. 
 
2.2.5 - In vivo MRI (including data analysis) 
All animal work was performed in accordance with the institutional animal protocol guidelines in place 
at the University Paris-Descartes (Saisine CEEA34.JS.142.1) and approved by the Institute’s Animal 
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Research Committee. Wild-type female 8 weeks BALB/c mice were anaesthetized by isoflurane 
inhalation (1.5% isoflurane in a 1:1 mixture of air and oxygen at the rate of 0.25 L min-1) and placed in a 
dedicated contention cradle in a 7 Tesla MR-scanner. 100 µL of iron oxide nanoparticles in saline 0.9 wt. 
% with an optimized concentration of [Fe] = 5 mM were intravenously injected via the tail vein thanks to 
a catheter specifically elaborated for non-magnetic use. The injected iron concentration was adjusted so 
that the hepatic uptake and clearance processes take a maximum of one week. For reproducibility 
studies, 2 to 4 mice were injected with the contrast agents tested. 13.2 nm citrate and PEG5K coated 
particles were injected on one mouse only. For imaging purposes, two types of time resolution were 
used sequentially: a high temporal resolution with low spatial resolution for the first 180 minutes, and a 
lower time resolution with high spatial resolution for time range between 20 min and 7 days. With this 
protocol, it was ensured that the early stage of the hepatic uptake could be evaluated accurately. The 
low spatial resolution scans were compared and normalized to the higher resolution images using a zero 
filling technique for signal optimization. All images were recorded with a field of view of 3 3 cm2, 
corresponding to an in-plane resolution of 125 125 µm2 in both sequences. The scanning protocol was 
developed using Paravision 5.1 software. To minimize motion artifacts, two methods of respiratory 
synchronization were used. The high spatial, low temporal resolution sequence synchronized the 
acquisition with the mouse breathing cycles. The low spatial, high temporal resolution sequence used an 
internal navigator that detects the mouse respiratory and cardiac cycles and reconstructs the images in 
a post-processing operation. This second method is independent of the breathing cycle changes. The 
time frame was set to one minute for the fast scans and three minutes for the slower scan. To 
recapitulate the chronological imaging experiments, images were recorded before injection and during 
the first 20 min at a rate of one image per minute, then at 30 min, 40 min, 1 h, 1h40, 2h40, 4h, 7h20 and 
at 1, 2, 3, 4 5, and 7 days after injection. 3 mice per days were investigated with the addition of 3 to 9 
mice in the follow-up process between one day and one week. To study the probe biodistribution, 
several organs including liver, spleen, kidney and arteries (Supporting Information S6) were monitored. 
Comparison with commercial Cliavist® was also performed. 
 
 
3 - Results and Discussion 
3.1 - Iron oxide based contrast agents and coating 
Iron oxide nanoparticles of diameters 6.8 nm and 13.2 nm were synthesized by alkaline co-precipitation 
of iron salts and subsequent oxidation into maghemite (-Fe2O3) and coated with different 
macromolecules.36,37 As coating agent, we used a statistical copolymer that combines multiple 
phosphonic acid groups and poly(ethylene glycol) chains on the same backbone. The full name of the 
polymer is poly(ethylene glycol methacrylate-co-dimethyl(methacryoyloxy) methyl phosphonic acid), 
abbreviated phosphonic acid PEG copolymer in the sequel of the paper. Synthesized by free radical 
polymerization (Specific Polymers®, France), the polymers were designed to strongly adsorb onto metal 
and metal oxide surfaces via the multiphosphonic acid groups.12 Copolymers with 2 kDa and 5 kDa PEG 
chains were synthesized and studied.  
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The aforementioned PEGylated copolymers were compared to other coating types, including citric acid 
and poly(acrylic acid) polymer (PAA). Citric acid is a well-known and widely used coating for inorganic 
particles. In the molecular imaging context, citrate coated particles were tested in a clinical phase I trial 
to evaluate their pharmacokinetics and safety.47 Poly(acrylic acid) in contrast was less studied and to our 
knowledge the biodistribution of PAA coated contrast agents was not reported yet. In vitro, it was 
shown that PAA coat is biocompatible and non-toxic, and that the charged polymer layer brings 
significant protection against protein adsorption and particle agglomeration.9,48-50 A recent in vivo study 
has revealed however acute effects on cardiovascular function.49 The chemical formulae, charge and 
molecular weights of the coating agents probed are summarized in Fig. 1b. More details on the coating 
and characterization methods are given in the M&M section.  
 
Important parameters for the particles are the total hydrodynamic diameter    and the coating 
thickness  , which were determined by light scattering (Table III). The polymer layers were found to 
have the same thickness for the 6.8 and for the 13.2 nm particles, and to agree with the brush 
structure.51,52 In good solvent conditions, PEG2K is a chain of gyration radius 1.3 nm,
53 whereas its fully 
stretched length is about 10 nm.  -values of 5 ± 1 nm (Table III) are intermediate and indicate that the 
chains at the surface are slightly stretched, typically by 40 – 50 %. The PEG5K layer on the 6.8 nm iron 
oxide has a thickness of 16 ± 2 nm, which corresponds to a higher stretched configuration.52 PAA layers 
have a thickness of 2 – 3 nm, as mentioned in earlier work.9,40,44,50  
 
nanoparticles coating hydrodynamic 
diameter      
nm 
Layer thickness 
  
nm 
 -Fe2O3 
6.8 nm 
bare 14 ± 1 0 
citrate 15 ± 1 0.5 ± 1 
PAA2K 18 ± 1 2 ± 1 
PEG2K 22 ± 1 4 ± 1 
PEG5K 46 ±3 16 ± 2 
     -Fe2O3 
13.2 nm 
bare 27 ± 1 0 
citrate 28 ± 1 0.5 ± 1 
PAA2K 33 ± 1 3 ± 1 
PEG2K 37 ± 2 5 ± 1 
PEG5K 44 ± 3 8.5 ± 2 
    Cliavist© 
4 nm 
carboxy 
dextran 
66 ± 4 aggregates 
     
Table III: Characteristics of the iron oxide particles used in this work.    denotes the particle hydrodynamic 
diameter and   the coating thickness as determined from dynamic light scattering measurements. Data for 
Cliavist® are from ref.
1
 The error bars denote here the standard deviations. 
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3.2 - Stability in physiological and culture media 
As for the evaluation of protein corona and particle agglomeration, the following protocol was 
applied.9,44 A few microliters of a concentrated dispersion are poured and homogenized rapidly in 1 mL 
of the solvent to be studied, and simultaneously the scattered intensity    and diameter    are 
measured by light scattering. After mixing, the measurements are monitored over a 2-hour period, and 
subsequent measurements are made after 24 hours and 1 week. Nanoparticles are considered to be 
stable if their hydrodynamic diameter    in a given solvent remains constant as a function of the time 
and equal to its initial value (given in Table III). Solvents surveyed here are DI-water (pH 7.4), phosphate 
buffer saline (PBS) and cell culture medium (Dulbecco’s Modified Eagle’s Medium, DMEM) with or 
without calf bovine serum. 
Stability assays were performed on bare and coated iron oxide nanoparticles (Fig. 2). The commercial 
contrast agent Cliavist® was used as a benchmark. Bare particles with diameters 6.8 nm and 13.2 nm are 
stable at pH 1.8 (the pH at which they are synthesized) and stabilized by surface charges. Under rapid 
dilution, the pH variation induces a modification of the electrostatic charges at their surfaces. At 
physiological pH, the dispersions are close to their isoelectric point54 (IP 6.7) and the particles are slightly 
positive. Bare particles hence aggregate due to van der Waals interactions. Citrate and carboxydextran 
(Cliavist®) coated particles are stable in PBS buffer. In culture media however, citrate coated particle 
precipitation occurs (Fig. 2) and it is attributed to the displacement of the ligands from the surfaces, as 
they are preferentially complexed by Ca2+ and Mg2+ divalent counterions.9 For Cliavist®, the 
destabilization also takes place and come from the loosely tethered carboxydextran chains at the iron 
oxide surface. The particles coated with polymers, either poly(acrylic acid) or phosphonic acid PEG 
copolymers exhibit in contrast an outstanding stability over time. The dispersions are found to remain 
stable for months. For particles with polymer coats, protein corona was also not detected.12,55 The 
stability results obtained in DMEM after one week are summarized in Fig. 2.  
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Figure 2: a) Hydrodynamic diameter    versus time for contrast agents after they have been diluted in Dulbecco’s 
Modiﬁed Eagle’s Medium (DMEM). For uncoated particles, and for particles coated with citrates, aggregation and 
precipitation occur rapidly, as indicated by the initial size increase. For cliavist®, the aggregation is slower, but is 
still visible on the time scale of a week. Particles coated with poly(acrylic acid) and phosphonic acid PEG copolymers 
were found to remain stable for months. b-e) Images of some selected iron oxide dispersions in DMEM after one 
week. Stability assays were performed at experiments at the weight concentration of 0.1 wt. %. 
 
3.3 - Relaxometry 
The longitudinal and transverse relaxivities    and    of the coated particles dispersed in DI-water and in 
cell culture medium were measured using   - and   -weighted MR images on a 7.0 T on a 300 MHz 
micro-imaging Bruker spectrometer. Dispersion weighted phantom images at molar concentration [Fe] 
= 0, 0.02, 0.05, 0.1, 0.2 and 0.5 mM were acquired, and their greyscale intensity was found to decrease 
with concentration, a result that is explained by the dipolar coupling between the magnetic moments 
and the water protons. In this range, the inverse of the relaxation times was found to vary linearly with 
[Fe], according to:            [Fe]      
   where     
  denotes the water longitudinal and transverse 
relaxation time.46,56 Fig. 3a and 3b display the transverse relaxivity    histograms for the two particle 
sizes and for the various coatings. Comparison with Cliavist® is also shown (Fig. 3c). The relaxivities      
and relaxivity ratios       are listed in the Supporting Information Section (S7).  
Data in Fig. 3 show that the particle core size has a strong impact on the contrast, as    passes from 62 
mM-1 s-1 to 171 mM-1 s-1 for uncoated particles, and from 74 mM-1 s-1 to 226 mM-1 s-1 for the PEGylated 
ones. This increase is in agreement with that reported in Vuong et al. 42 who suggested that the iron 
based contrast agent transverse relaxivity grows quadratically with particle size. As for the coating, the 
data also show that the presence of a layer around particles leaves    rather unchanged and increases    
by 20% in average. With respect to the solvent, the effect is the strongest with uncoated particles. From 
DI-water to cell culture medium, the transverse relaxivity of 6.8 nm -Fe2O3 is multiplied by a factor of 4 
(from 62 mM-1 s-1 to 284 mM-1 s-1), whereas it is increased by a factor of 1.5 for the 13.2 nm particles 
(from 171 to 272 mM-1 s-1). This increase is consistent with particles being incorporated into large 
micron-sized aggregates, as shown in Fig. 2.42,57 In conclusion, we have found that for maghemite the 
coating has a relatively weak impact on    and   . These findings are important for the later in vivo MR 
imaging results, as they suggest that the role of the coating can be determined independently of other 
parameters.  
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Figure 3: Transverse relaxivity    measured at 7 Teslas for 6.8 nm (a) and 13.2 nm (b) iron oxide nanoparticles 
dispersed in aqueous media. The data for Cliavist® (c) are shown for comparison. The error bars are defined as the 
standard deviations. 
 
 
3.4 - Biocompatibility and toxicity 
Murine hepatocyte cells BWTG3 viability was studied using the colorimetric assay WST-1. WST-1 was 
performed at iron dose levels between 10-3 mM to 10 mM, to cover a broad concentration range and 
specifically the concentration used in vivo ([Fe] = 0.5 mM in the blood pool). Fig. S8 a-f display the 
percentage of viable BWTG3 cells treated during 24 h with Cliavist® and with the 6.8 nm and 13.2 nm 
iron oxides. For the 11 particles studied, the viability exhibits a slight to moderate decrease around [Fe] 
= 0.5 - 5 mM, the effect being the strongest for bare and citrate coated particles. This latter result could 
be related to the particle agglomeration and sedimentation, which increase the amount of materials 
adsorbed at the plasma membrane.55 Observations of cells in situ using optical microscopy indicate that 
the cellular morphology was modified at high dose levels. Except for bare particles, the BWTG3 
hepatoma cells exhibit a viability above 50% for all coating. These findings corroborate results obtained 
with other cell lines, including NIH/3T3 mouse fibroblasts,50 2139 Human lymphoblasts9 and RAW264.7 
macrophages.12 Viability experiments with the coating agents alone, including phosphonic acid PEG 
copolymers, citrate and PAA polymers, were also done and reveal no cytotocity at relevant 
concentrations.9,12,50  
 
3.5 -   -weighted MR Imaging of the liver: particle size and coating effects 
The uptake of intravenously injected contrast agents was monitored by measuring the signal 
enhancement on T2 weighted images of different organs. The iron oxide dispersion injected to the 
mouse was 100 µL and the iron concentration 5 mM (corresponding to 16.7 µmol kg-1 or 0.93 mg kg-1). 
Previous reports have shown that iron oxide based contrast agents exhibit uptake times of the order of 
minutes and clearance times in the range of days.21-23,58-60 A logarithmic temporal scale was hence used 
for imaging the mouse organs at times ranging from one minute to one week. Fig. 4 compares MR scans 
obtained in the first three hours for Cliavist® (Fig. 4a to d) and for the 6.8 nm PEG2K particles (Fig. 4e to 
h). With the commercial agent, the mouse liver section exhibits a negative contrast enhancement 
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shortly after injection (e.g. in Fig. 4b at 30 min). The darkening in the liver arises from the iron 
accumulation in the organ.1,21,22,58,60-63 Multi-phosphonic acid PEG coated particles display a different 
behavior (Fig. 4e-g). For this sample the darkening is delayed by about 2 – 3 hours as compared to that 
of Cliavist®. During the period, the MR images show no contrast change of the liver and of other organs 
(spleen, kidneys), indicating a prolonged circulation in the bloodstream, as well as a delayed hepatic 
uptake (S6). At 3 hours post-injection (Fig. 4d and 4h), MR images exhibit a negative contrast 
enhancement as with cliavist®. A movie comparing the liver MRI intensity after injection of PAA2K and 
multi-phophonic acid PEG2K coated particles has been added as Supporting Information. 
 
 
Figure 4: Magnetic resonance imaging scans for wild-type female 8 weeks BALB/c mouse livers at different time 
points (30 min, 1 and 3 hours) after injection for Cliavist® (a to d) and for the 6.8 nm PEG2K coated particles (e to h). 
In the assays, 100 µL of a [Fe] = 5 mM dispersion were injected to the mouse. The corresponding dose is 16.7 
µmoles, or equivalently 0.93 mg of iron per kilogram of mouse. A comparison of the two time sequences shows a 
delay in the negative contrast enhancement at about 3 hours for the PEG particles, compared to that of the 
commercial contrast agent. 
 
 
To quantify the MR contrast, the liver mapping was performed by defining manually regions of interest 
(ROI), and by integrating the grey scale intensity as an 8-bit integer (between 0 and 255). Spatially 
average intensities were obtained and normalized with respect to the pre-injection level. With these 
conventions, the MRI signal intensity varies between 1 and 0, and the liver darkening is associated with 
a decrease as a function of the time (Fig. 5). The procedure was carried out at each time point for 8 
particles: cliavist® (  = 3), 6.8 nm particles coated with PAA2K (  = 3), PEG2K (  = 4) and PEG5K (  = 2), and 
with 13.2 nm coated with citrate (  = 1), PAA2K (  = 2), PEG2K (  = 2) and PEG5K (  = 1). Here,   
designates the number of mice tested. Intravenous injection into the tail vein was performed as a single 
bolus in the conditions of Fig. 4, i.e. 100 µL of dispersion at 5 mM. Fig. 5 illustrates the correspondence 
between the liver MR images and the greyscale intensity. In the pre-injection period, the intensity 
remains at the level of 1. The MR signal then decreases rapidly after injection and passes through a 
minimum.  
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Figure 5: a) to c) Magnetic resonance imaging scans of a wild-type female 8 week BALB/c mouse liver at different 
time points after injection for the 13.2 nm poly(acrylic acid) coated particles. The liver mapping (indicated as ROI in 
the images) was performed manually by defining regions of interest, and by integrating the greyscale intensity as 
an 8-bit integer. d) Illustration of the correspondence between the MR images and the greyscale intensity displayed 
in the left-hand side panel. In the pre-injection period, the intensity remains constant and then decreases rapidly 
after injection.  
 
 
In Fig. 6a and 6b, data for 6.8 nm and 13.2 nm particles coated with PAA2K and PEG2K are compared. For 
the poly(acrylic acid) coated nanoparticles, as well as for Cliavist®, the MRI signal intensity exhibits a 
broad minimum down to 0.35. For these samples, the minimum extends over a period of tens to 
hundreds of minutes. At longer timescale, typically from 1 to 7 days after injection the MRI signal 
intensity increases again and reaches unity, indicating that the liver returns to its pre-injection level. This 
recovery is associated with the iron clearance out of the liver.21,58-60 On the opposite, PEGylated 6.8 nm 
and 13.2 nm particles exhibit prolonged circulations in the blood pool, the contrast enhancement 
appearing approximately after 2 – 3 hours. Later, the MRI signal passes through a minimum as in the 
previous case, and recovers its pre-injection limit after a few days. Interestingly, the MRI level at the 
minimum (around 0.6) remains higher than for anionic particles, indicating a lower iron oxide 
concentration and a reduced uptake 
Concerning the polymer molecular weight, earlier studies have shown that the coating efficiency 
increases with the layer thickness.1-3,6,15,23,25,26 To test this assumption, the pharmacokinetics of identical 
core particles with 2 kDa and 5 kDa PEG coating was investigated. From light scattering experiments, the 
layer thickness associated to PEG2K and PEG5K polymers was estimated at 5 nm and 8 nm, respectively 
(Table III). Fig. 7a and 7b compare the MRI signal intensity for the two particles. For 6.8 nm particles, the 
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hepatic uptake is progressive and slightly more rapid for PEG5K than for PEG2K. The difference may come 
from the hydrodynamic diameter that is about twice larger with the longer polymer, or from a lower 
PEG density (S5). For the 13.2 nm particles, the time dependent contrast enhancements remain similar 
in terms of hyposignal kinetics and amplitude. Combined together, these results show that the optimum 
stealthiness in vivo is obtained for the 6.8 nm particles and a 2 kDa PEG coating.  
 
    
Figure 6: Time dependences of the MRI signal intensity for a) 6.8 nm and b) 13.2 nm PAA2K and PEG2K coated 
nanoparticles. Cliavist® is shown for comparison. In the in vivo experiments, the iron oxide dispersion injected to the 
mouse was 100 µL and the iron concentration 5 mM (corresponding to 16.7 µmol kg
-1
 or 0.93 mg kg
-1
). With the 
conventions used, the darkening of the liver is associated to a decrease of the MRI signal as a function of the time. 
The error bars indicate the standard deviations. 
Figure 7: Time dependences of the MRI signal intensity for a) 6.8 nm and b) 13.2 nm nanoparticles coated with 
PEG2K and PEG5K. Cliavist® is shown for comparison. The experimental conditions are similar to those of Fig. 6. The 
error bars indicate the standard deviations. 
 
3.6 - Quantitative analysis of iron uptake and release by the liver  
To retrieve the contrast agent pharmacokinetics parameters, the MRI signal intensity was adjusted using 
an expression of the form:  
                     
 
   
 
 
                
 
      
 
 
    (2) 
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where   is the intensity minimum,     and        the characteristic times for uptake and clearance. In 
the above model, it is assumed that the two mechanisms are occurring one after the other. In a first 
attempt to adjust the MRI intensities, single exponentials were used but were found to be 
inappropriate. The single exponentials were replaced by stretched exponentials characterized by 
exponents   for the uptake and   for the clearance. Stretched exponential functions have been found to 
describe many phenomena in Nature, in particular in complex systems with broad relaxation time 
distribution.64,65 In Eq. 2,     and        are related respectively to the half-life times     
  
 and     
      that 
characterize the initial and terminal processes, via the expressions     
           
    and     
      
           
   . In the following, the data will be discussed in terms of the half-life times to ease 
comparison with earlier work.23,58 Fig. 8a–h show the MRI signal intensities obtained for the different 
systems and the least-square calculations results using Eq. 2 (continuous lines). For the eight samples 
considered, Eq. 2 provides a satisfactory outcome over the entire time range. The adjustable parameters 
 , the half-life times     
  
 and     
     , and the stretched exponents   and   are listed in Table IV.  
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Figure 8: MRI signal intensity for the iron based contrast agents studied in this work, together with least-square 
calculations using Eq. 2 (continuous lines). The fitting of the uptake and clearance kinetics allows to determine the 
following parameters: the intensity minimum  , the half-life times     
  
 and     
      and the stretched exponents   
and   (Table IV).  
 
 
As anticipated, the half-life time     
  
 for the uptake mechanism depends strongly on the coating. For 
PAA2K 6.8 nm particles, the uptake time is estimated at 4.5 ± 0.3 min, whereas it is 55 times longer for 
PEG2K particles, at 249 ± 18 min. The stretch exponent for this mechanism varies from           for 
the agents that are rapidly uptaken, to     for the stealthiest ones. In Table IV, the size effect can be 
clearly seen as 6.8 nm particles have systematically prolonged circulation times as compared to the 13.2 
nm particles.1 The results suggest that the uptake mechanism depends primarily on two parameters, the 
probe size and the coating type. In the present study, the effects of each of these parameters are 
separately identified.  
 
The clearance phenomenon is associated with the particle degradation and with the iron incorporation 
into the main intracellular iron storage proteins (ferritin, hemosiderin).58,59 The MRI signal intensity 
returns to its pre-injection level as iron oxide particles are metabolized and their degradation products 
cleared (Fig. 8). As can be seen from Table IV, a rather uniform kinetics is observed for the clearance, 
with half-life times between 2 to 4 days. Indeed,     
      does not depend on the magnetic core sizes, nor 
on the coating. The benchmark agent Cliavist® exhibits also a comparable clearance time (    
      = 2.6 ± 
0.1 day).  
 
 -Fe2O3 coating       
  
 
(min) 
      
      
(day) 
  
6.8 nm PAA2K 0.45 4.5 ± 1.3 0.46 2.8 ± 0.2 1.6 
PEG2K 0.62 249 ± 18 3.0 4.0 ± 0.3 1.4 
PEG5K 0.65 103 ± 15 1.2 1.5 ± 0.3 1.6 
       13.2 nm citrate 0.40 2.5 ± 0.2 0.42 3.9 ± 0.2 1.0 
PAA2K 0.30 1.4 ± 0.3 0.60 2.8 ± 0.3 0.4 
PEG2K 0.50 82 ± 13 0.80 2.8 ± 0.6 1.8 
PEG5K 0.54 59 ± 15 1.2 n.d. n.d. 
       Cliavist® Carboxy 
dextran 
0.42 6.0 ± 1.2 0.40 2.6 ± 0.1 1.3 
        
Table IV: Parameters obtained from the adjustment of the MRI signal intensity with Eq. 2.   denotes the intensity 
minimum,     
  
 and     
      the half-life times associated to the uptake and clearance mechanisms and   and   the 
stretched exponential exponents. The error bars are defined as the standard deviations (SD). 
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4 - Conclusion 
In this work, novel iron oxide based contrast agents dedicated to in vivo magnetic resonance imaging 
were synthesized, with the aim of understanding the relationship between the particle coating 
properties and their pharmacokinetics. Maghemite (-Fe2O3) particles with diameters 6.8 nm and 13.2 
nm were prepared and coated following bottom-up assembly processes. Different organic 
macromolecules were considered and a total of 10 different probes were evaluated both in vitro and in 
vivo. Statistical copolymers (Specific Polymers®, France) combining multiple phosphonic acid groups and 
PEG chains on the same backbone were synthesized and used as coats for iron oxide particles. These 
polymers were characterized by 2 kDa and 5 kDa PEGylated side-chains.  
The particles were first evaluated regarding their physico-chemical properties and characterized in 
terms of size, charge and coating thickness. The colloidal stability, protein adsorption in culture media, 
contrast agent relaxometry and probe toxicity were investigated. The first result that emerges from the 
in vitro assay is that polymers, either poly(acrylic acid) or poly(ethylene glycol) are efficient coatings, as 
they prevent particles to agglomerate in culture media or to be covered by plasma proteins. The 
particles and the PEG based polymers were found to be non-toxic and biocompatible at the in vivo dose 
level. 
The dispersions were injected intravenously into the mouse tail vein at a relatively low dose (16.7 µmol 
of iron per kilogram of mouse) compared to earlier reports. Liver, spleen and kidneys   -MR images 
were acquired prior and after injection, at time points between one minute and seven days. As 
nanoparticles are eliminated by the reticulo-endothelial system and filtered by the liver, the change in 
the liver MRI contrast was investigated and provided a direct indication of the nanoparticle 
pharmacokinetics. With this protocol, the particle uptake and clearance time evolution in and out of the 
liver could be retrieved. The main outcome from the in vivo MRI mouse assays is that coating appears as 
the primary parameter that affects the liver uptake kinetics and elimination from the blood pool. 
Phosphonic acid PEG2K-copolymers provides the most efficient contrast agent in terms of stealthiness, as 
they are able to prolong the blood particle lifetime up to 250 minutes. In similar conditions, the life 
times for citrate and PAA2K coated particles are typically 50 times shorter. Although poly(acrylic acid) is a 
robust coating ensuring colloidal stability in vitro, its in vivo performance is comparable to that of citrate 
or dextran. The time at which the MRI signal intensity returns to its pre-injection level was found to 
follow a more universal behavior. The clearance time was comprised between 2 to 4 days for all samples 
studied, including the commercial benchmark Cliavist®. In conclusion, we have shown that a 5 nm layer 
made of multi-phosphonic acid poly(ethylene glycol) at the iron oxide surface significantly improve the 
colloidal stability, protein adsorption properties and stealthiness in vivo of MRI probes. Our work also 
demonstrates that the phosphonic acid coupled to innovative polymer synthesis may open up new 
horizons regarding the surface functionalization. 
 
Supporting Information 
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The Supporting Information includes sections on the iron oxide nanoparticle characterization in S1 
(transmission electron microscopy), S2 (electron beam microdiffraction), S3 (vibrating sample 
magnetometry) and S4 (zeta potential). The PEG density determination at the particle surface is 
described in S5, the nanoparticle distribution kinetics in abdominal aorta in S6, the longitudinal and 
transverse relaxivity measurements in S7 and the cytotoxicity studies using murine hepatocytes in S8. 
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